S. Broder

发表

The Sequence of the Human Genome

Timothy B. Stockwell, William H. Majoros, Helen M. Moore, 2001, Science.

The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention.

S. Broder, J. Karp, Samuel Broder, 1992, Leukemia & lymphoma.

Implications of new proteomics strategies for biology and medicine.

Bruno Domon, S. Broder, B. Domon, 2004, Journal of proteome research.

A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens.

A. Tutt, Sheng-Yung P. Chang, J. Sninsky, 2009, The Journal of molecular diagnostics : JMD.

Implications of the human genome for understanding human biology and medicine.

M. Adams, J. Venter, M. Adams, 2001, JAMA.

Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia.

T. Waldmann, S. Broder, M. Durm, 1974, Lancet.

Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro.

S. Broder, I. Magrath, H. Kirchner, 1979, Journal of immunology.

Molecular targets for AIDS therapy.

H. Mitsuya, S. Broder, R. Yarchoan, 1990, Science.

The Genome Sequence of the Malaria Mosquito Anopheles gambiae

Jian Wang, Eugene W. Myers, Andrew G. Clark, 2002, Science.

Ovarian cancer: screening, treatment, and followup.

Robert C. Bast, Robert W. Makuch, Alice S. Whittemore, 1995, NIH consensus statement.

Oncology and hematology.

S. Broder, J. Karp, 1994, JAMA.

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.

W. Wilson, S. Steinberg, S. Broder, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.

S. Steinberg, B. Anderson, H. Mitsuya, 1995, The Journal of infectious diseases.

The immunology of HIV infection: implications for therapy.

H. Mitsuya, S. Broder, R. Yarchoan, 1992, AIDS research and human retroviruses.

Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development.

S. Broder, R. Yarchoan, 1992, Journal of enzyme inhibition.

Initial Clinical Experience with Dideoxynucleosides as Single Agents and in Combination Therapy

H. Mitsuya, S. Broder, C. Perno, 1990, Annals of the New York Academy of Sciences.

Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

M. Reitz, H. Mitsuya, G. Zon, 1987, Proceedings of the National Academy of Sciences of the United States of America.

ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

E. Gelmann, H. Mitsuya, S. Broder, 1986, The Lancet.

3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.

E. De Clercq, R. Pauwels, P. Herdewijn, 1987, Journal of medicinal chemistry.

Rapid Communication—The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses—Report of the 1991 Bethesda Workshop

S. Broder, 1992 .

Synthesis and anti-HIV activity of isonucleosides.

H. Mitsuya, D. Huryn, S. Broder, 1992, Journal of medicinal chemistry.

Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro

D. Norbeck, H. Mitsuya, S. Broder, 1990, Antimicrobial Agents and Chemotherapy.

Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells.

H. Mitsuya, S. Broder, F. Wong-Staal, 1988, Science.

The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides.

E. De Clercq, P. Herdewijn, S. Broder, 1987, Molecular pharmacology.

1044 CD4 RECEPTORS IN INFECTION OF MONOCYTES BY HIV hanced by low

M. Baseler, S. Broder, C. Perno, 2003 .

Estrogen Receptor Genotypes and Haplotypes Associated with Breast Cancer Risk

Bjarni V. Halldórsson, B. Halldórsson, A. Clark, 2004, Cancer Research.

From the National Institutes of Health.

S. Broder, S. Broder, 1992, JAMA.

Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associa

R. Redfield, S. Broder, R. Yarchoan, 1986, The Journal of clinical investigation.

T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners.

J. Ghrayeb, S. Broder, J. Lähdevirta, 1989, AIDS.

Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome.

J. Goedert, E. Sondik, M. Gail, 1991, Journal of the National Cancer Institute.

Perspectives in CancerResearch Acquired Immunodeficiency Syndrome and Non-Hodgkin's Lymphomas

S. Broder, J. Karp, 1991 .

Abnormal Immunoregulation in Pediatric Cancer and Immunodeficiency

S. Broder, 1981 .

The Sézary syndrome: a malignant proliferation of helper T cells.

T. Waldmann, R. Macdermott, S. Broder, 1976, The Journal of clinical investigation.

Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells.

G. Zon, S. Broder, W. Egan, 1992, Antisense research and development.

Human T-cell leukemia/lymphoma viruses (HTLV): a unique family of pathogenic retroviruses.

H. Mitsuya, S. Broder, 1985, Current topics in microbiology and immunology.

NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus.

T. Waldmann, E. Jaffe, V. Devita, 1984, Annals of internal medicine.

IMMUNE T CELLS REACTIVE AGAINST HUMAN T-CELL LEUKAEMIA/LYMPHOMA VIRUS

H. Mitsuya, S. Broder, L. Matis, 1984, The Lancet.

Clinical Features of Human T-Cell Leukemia/Lymphoma Virus (HTLV) Associated T-Cell Neoplasms

H. Mitsuya, S. Broder, 1984 .

Human T-Cell Retrovirus and Adult T-Cell Lymphoma and Leukemia: Possible Factors on Viral Incidence

M. Wainberg, S. Broder, Yoshiaki Ito, 1983 .

Neoplasms of immunoregulatory T cells in clinical investigation.

T. Waldmann, S. Broder, L. Muul, 1980, The Journal of investigative dermatology.

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

H. Moss, J. Falloon, A. Brunetti, 1988, The New England journal of medicine.

Clinical Pharmacokinetics of Suramin in Patients With HTLV‐III/LAV Infection

R. Redfield, A. Fauci, H. Lane, 1986, Journal of clinical pharmacology.

Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

H. Mitsuya, G. Zon, S. Broder, 1989, Proceedings of the National Academy of Sciences of the United States of America.

A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

T. Waldmann, S. Broder, T. Uchiyama, 1981, Journal of immunology.

Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas.

S. Broder, J. Karp, 1991, Cancer research.

Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system.

T. Waldmann, S. Broder, Thomas A. Waldmann, 1982, Advances in immunology.

X-linked hypogammaglobulinemia and isolated growth hormone deficiency.

T. Waldmann, S. Broder, J. Mulvihill, 1980, The New England journal of medicine.

Molecular Foundations of Oncology

S. Broder, 1992, Annals of Internal Medicine.

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

S. Broder, T. Shirasaka, H. Mitsuya, 1993, The Journal of clinical investigation.

Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30)

T. Waldmann, S. Broder, D. Mann, 1980, The Journal of experimental medicine.

Metabolic heterogeneity of eosinophils from normal and hypereosinophilic patients.

S. Broder, S. Pincus, W. Schooley, 1981, Blood.

Serum immunoglobulin E levels in patients with neoplastic disease.

T. Waldmann, J. Bull, S. Broder, 1974, Journal of immunology.

PROTEIN‐LOSING ENTEROPATHIES IN MALIGNANCY

T. Waldmann, S. Broder, W. Strober, 1974, Annals of the New York Academy of Sciences.

Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma.

A. Foli, S. Broder, P. Adamson, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells.

S. Broder, M. Connelly, M. Johnson, 1988, The Journal of biological chemistry.

Mutation Screening of the TNFRSF11A Gene Encoding Receptor Activator of NFkB (RANK) in Familial and Sporadic Paget's Disease of Bone and Osteosarcoma

M. Adams, A. Sparks, J. Venter, 2001, Calcified Tissue International.

Inhibitory activity of antibodies to human Ia-like determinants: comparison of intact and pepsin-digested antibodies.

S. Broder, D. Mann, J. Decker, 1983, Journal of immunology.

Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma.

A. Foli, S. Broder, R. Yarchoan, 1993, Journal of the National Cancer Institute.

High molecular weight antigens present on human T cells.

J. Strominger, S. Broder, L. Chess, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′‐dideoxycytidine (ddc)

M. Dalakas, S. Broder, R. Dubinsky, 1989, Muscle & nerve.

Perspectivesin CancerResearch Acquired Immunodeficiency Syndrome and Non-Hodgkin's Lymphomas

S. Broder, E. Karp, Judith, 2006 .

Perspective: The expanding challenge of HIV‐associated malignancies

S. Broder, J. Karp, 1992, CA: a cancer journal for clinicians.

The suppressor-cell network in cancer (second of two parts).

T. Waldmann, S. Broder, 1978 .

Polyclonal Activation of Human B Lymphocytes by Nocardia Water Soluble Mitogen (NWSM)

T. Waldmann, S. Broder, C. Bona, 1979, Immunological reviews.

Phosphoroselenoate oligodeoxynucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity.

J. Toulmé, S. Broder, C. Stein, 1989, Nucleic acids research.

Current concepts in immunoregulatory T-cell neoplasms.

T. Waldmann, S. Broder, T. Uchiyama, 1979, Cancer treatment reports.

A MALIGNANT PROLIFERATION OF HELPER T CELLS

T. Waldmann, R. Macdermott, S. Broder, 1976 .

Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I).

M. Reitz, H. Mitsuya, S. Broder, 1984, Science.

Regulation of synthesis of immunoglobulins

T. Waldmann, S. Broder, M. Durm, 1976 .

Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells.

T. Waldmann, S. Broder, M. Durm, 1975, The New England journal of medicine.

Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition.

Samuel H. Wilson, S. Broder, S. H. Wilson, 1988, The Journal of biological chemistry.

Evolution of a lymphoma with helper T cell characteristics in Sézary syndrome.

T. Waldmann, E. Jaffe, S. Broder, 1978, Blood.

Cytogenetic studies in human T-cell lymphoma virus (HTLV)-positive leukemia-lymphoma in the United States.

W. Blattner, E. Jaffe, E. Gelmann, 1985, Journal of the National Cancer Institute.

Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma.

M. Reitz, S. Broder, D. Mann, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of lymphoblast Fc receptor expression in acute lymphoblastic leukemia.

S. Broder, G. Reaman, W. Pichler, 1979, Blood.

Trial of Antisense RNA Inhibition of HIV Replication and Gene Expression

H. Mitsuya, S. Broder, A. Nienhuis, 1991 .

Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells.

T. Waldmann, S. Broder, C. Goldman, 1981, The New England journal of medicine.

Characteristics of Multiple Myeloma as an Immunodeficiency Disease

T. Waldmann, S. Broder, 1980 .

In Vitro Functions of Human T Cells Expressing Fc‐IgG or Fc‐IgM Receptors

S. Broder, W. Pichler, 1981, Immunological reviews.

Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages

A. Foli, S. Broder, C. Perno, 1992 .

Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages.

A. Foli, S. Broder, C. Perno, 1992, Blood.

Synthesis and Anti‐HIV Activity of a Novel Series of Isomeric Dideoxynucleosides

D. Richman, H. Mitsuya, D. Huryn, 1990 .

Anabolism and Mechanism of Action of Ro24‐5098, an Isomer of 2′,3′‐Dideoxyadenosine (ddA) with Anti‐HIV Activity

D. Richman, H. Mitsuya, D. Huryn, 1990, Annals of the New York Academy of Sciences.

Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine.

H. Mitsuya, S. Broder, J. Tomaszewski, 1990, Reviews of infectious diseases.

Dideoxycytidine: current clinical experience and future prospects. A summary.

S. Broder, R. Yarchoan, 1990, The American journal of medicine.

In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors

T. Chou, H. Mitsuya, S. Broder, 1990, Antimicrobial Agents and Chemotherapy.

(±)-Dioxolane-T ((±)-1-[(2β,4β)-2-(hydroxymethyl)-4-dioxolanyl]thymine): a new 2',3'-dideoxynucleoside prototype with in vitro activity against HIV

D. Norbeck, H. Mitsuya, S. Broder, 1989 .

Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.

S. Broder, C. Perno, M. Sarngadharan, 1988, Molecular pharmacology.

Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin‐like growth factor in HIV‐infected patients

D. Longo, M. Baseler, D. Venzon, 1998, AIDS.

Twenty-Five Years of Translational Medicine in Antiretroviral Therapy: Promises to Keep

S. Broder, 2010, Science Translational Medicine.

Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection.

S. Broder, P. D. Smith, S. Wahl, 1990, Blood.

Pharmacokinetics of 2′, 3′‐dideoxyadenosine and 2′, 3′‐dideoxyinosine in patients with severe human immunodeficiency virus infection

S. Broder, R. Yarchoan, J. Pluda, 1990, Clinical pharmacology and therapeutics.

Ic issues in anti-retrovirai lherapy

H. Mitsuya, S. Broder, R. Yarchoan, 1990 .

Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related Disorders

S. Broder, R. Yarchoan, C. Myers, 1988, Journal of clinical pharmacology.

Progress in drug therapies for HIV infection.

A. Fauci, S. Broder, 1988, Public health reports.

PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)

H. Mitsuya, S. Broder, B. Safai, 1988, The Lancet.

Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity.

T. Waldmann, S. Broder, R. Blaese, 1978, Annals of internal medicine.

The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions.

S. Broder, W. Strober, S. Polmar, 1977, The Journal of clinical investigation.

Suramin and function of the adrenal cortex.

E. Gelmann, S. Broder, C. Stein, 1986, Annals of internal medicine.

Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido- 2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine

D. S. Webb, H. Mitsuya, S. Broder, 1989, The Journal of experimental medicine.

Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus

P. Bunn, H. Mitsuya, S. Broder, 1983, The Journal of experimental medicine.

Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage.

A. Foli, S. Broder, R. Yarchoan, 1994, Blood.

Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma

T. Waldmann, E. Jaffe, V. Devita, 1981 .

The challenge of cancer research

S. Broder, 1993, Stem cells.

Chemotherapy for lymphoma in a patient with common variable immunodeficiency: case report, literature review, and recommendations for chemotherapy in immunodeficient patients.

E. Jaffe, E. Gelmann, S. Broder, 1982, Archives of internal medicine.

Corticosteroid-responsive intestinal lymphangiectasia secondary to an inflammatory process.

T. Waldmann, S. Broder, A. Muchmore, 1979, The New England journal of medicine.

The suppressor-cell network in cancer (second of two parts).

T. Waldmann, S. Broder, 1978 .

Suppressor cells in the regulation of the immune response.

T. Waldmann, S. Broder, 1977, Progress in clinical immunology.

Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies

M. Baseler, S. Broder, C. Perno, 1990, The Journal of experimental medicine.

Strategies for experimental therapy of the retrovirus which causes aids

S. Broder, 1987 .

Strategies for the future chemotherapy of human immunodeficiency virus (HIV).

S. Broder, 1987, Haematology and blood transfusion.

Transformation and cytopathogenic effect in an immune human T-cell clone infected by HTLV-I.

M. Reitz, H. Mitsuya, S. Broder, 1984, Science.

Designing CD4 immunoadhesins for AIDS therapy

H. Mitsuya, S. Broder, F. Wurm, 1989, Nature.

Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS.

M. Clerici, S. Broder, C. Hendrix, 1993, The Journal of infectious diseases.

Neoplasms of immunoregulatory cells.

T. Waldmann, S. Broder, T. Uchiyama, 1979, American journal of clinical pathology.

Evolution of a lymphoma with helper T cell characteristics in Sézary syndrome.

T. Waldmann, E. Jaffe, S. Broder, 1978, Blood.

Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor

W. Greene, S. Broder, R. Gallo, 1983, Nature.

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

H. Mitsuya, S. Broder, J. Mcmahon, 1986, Biochemical pharmacology.

Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro.

H. Mitsuya, S. Broder, T. Shirasaka, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

H. Mitsuya, S. Broder, S Broder, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacokinetics of 2',3' ‐dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications

S. Broder, R. Yarchoan, K. Wyvill, 1991, Clinical pharmacology and therapeutics.

Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV.

S. Broder, C. Stein, J. Cohen, 1989, AIDS research and human retroviruses.

Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase.

R. Miller, J. Hoofnagle, H. Mitsuya, 1989, Gastroenterology.

Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro.

H. Mitsuya, S. Broder, 1988, AIDS research and human retroviruses.

2', 3'-Dideoxynucleoside Analogues : Development of Anti-Viral Therapy for HTLV-III/LAV Associated Diseases

H. Mitsuya, S. Broder, R. Yarchoan, 1986 .

Pharmacological inhibition of infectivity of HTLV-III in vitro.

S. Matsushita, H. Mitsuya, S. Broder, 1985, Cancer research.

Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.

S. Broder, D. Cooney, A. Fridland, 1991, Molecular pharmacology.

2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis.

S. Broder, J. Cupp, J. Balzarini, 1987, Molecular pharmacology.

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

S. Broder, D. Cooney, A. Fridland, 1987, Biochemical pharmacology.

Fc-Receptors on Human T Lymphocytes I. Transition of Tγ to Tµ Cells

S. Broder, W. Pichler, L. Lum, 1978 .

DYSFUNCTION OF SUPPRESSOR MECHANISMS ASSOCIATED WITH IMMUNODEFICIENCY AND AUTOIMMUNITY

T. Waldmann, S. Broder, M. Durm, 1977 .

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex

H. Mitsuya, S. Broder, R. Yarchoan, 1990, The Lancet.

The pharmacokinetics of zidovudine administered by continuous infusion in children.

J. Falloon, S. Broder, R. Murphy, 1989, Annals of internal medicine.

Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases

S. Broder, R. Yarchoan, J. Jenkins, 1987, Clinical pharmacology and therapeutics.

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Broder, H. Mitsuya, S. Broder, 1986, Proceedings of the National Academy of Sciences of the United States of America.

1-(2,3-Anhydro-beta-D-lyxofuranosyl)cytosine derivatives as potential inhibitors of the human immunodeficiency virus.

H. Mitsuya, S. Broder, T. Webb, 1988, Journal of medicinal chemistry.

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

D W Barry, H. Mitsuya, S. Broder, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro.

H. Mitsuya, S. Broder, S. Phadtare, 1988, Proceedings of the National Academy of Sciences of the United States of America.

The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.

E. De Clercq, R. Pauwels, P. Herdewijn, 1988, Biochemical pharmacology.

17 – Toward the Rational Design of Antiretroviral Therapy for Human Immunodeficiency Virus (HIV) Infection

H. Mitsuya, S. Broder, 1991 .

Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T‐cell lymphotropic virus (HTLV‐III)/lymphadenopathy‐associated virus (LAV)

E. De Clercq, H. Mitsuya, S. Broder, 1986, International journal of cancer.

CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.

A. Tsiatis, S. Steinberg, D. Venzon, 1991, Annals of internal medicine.

Developmental therapeutics and the acquired immunodeficiency syndrome.

V. Devita, A. Fauci, J. Kovacs, 1987, Annals of internal medicine.

Textbook of AIDS Medicine

T. Merigan, S. Broder, D. Bolognesi, 1994 .

Human T-cell leukemia viruses (HTLV): a unique family of pathogenic retroviruses.

S. Broder, R. Gallo, 1985, Annual review of immunology.

A pathogenic retrovirus (HTLV-III) linked to AIDS.

S. Broder, R. Gallo, 1984, The New England journal of medicine.

Association of the human type C retrovirus with a subset of adult T-cell cancers.

W. Blattner, E. Jaffe, R. Fisher, 1983, Cancer research.

Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus.

E. De Clercq, H. Mitsuya, S. Broder, 1986, Biochemical and biophysical research communications.

CUTANEOUS T-CELL LYMPHOMAS

P. Bunn, S. Broder, 1976, The Lancet.

Molecular foundations of cancer: New targets for intervention

S. Broder, J. Karp, 1995, Nature Medicine.

Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report.

S. Broder, R. Yarchoan, 1987, The New England journal of medicine.

Characterization of a suppressor-cell leukemia. Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells.

T. Waldmann, J. Whang‐Peng, S. Broder, 1978, The New England journal of medicine.

Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia.

T. Waldmann, S. Korsmeyer, S. Broder, 1983, The Journal of clinical investigation.

Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy.

S. Steinberg, S. Broder, I. Feuerstein, 1990, Annals of internal medicine.

Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS‐related complex

S. Broder, R. Yarchoan, P. Miranda, 1989, Clinical pharmacology and therapeutics.

Factors in the development of AIDS-related lymphomas.

S. Broder, 1992, Leukemia.

Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

S. Matsushita, H. Mitsuya, S. Broder, 1984, Science.

lmmunologic Enhancement of Tumor Xenografts by Pepsin-Degraded Immunoglobulin

S. Broder, F. Whitehouse, 1968, Science.

Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.

H. Mitsuya, S. Broder, J. Roth, 1990, Journal of medicinal chemistry.

Synthesis and Evaluation of 2′,3′-Dideoxy-9-Deazaadenoslne and Some Related Derivatives

S. Broder, R. Klein, S. Tam, 1989 .

Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides.

S. Broder, R. Yarchoan, 1989, Pharmacology & therapeutics.

The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

S. Broder, Samuel Broder, 2010, Antiviral research.

AIDS, modern concepts and therapeutic challenges

S. Broder, Samuel Broder, 1987 .

Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.

H. Mitsuya, S. Broder, V. Marquez, 1987, Journal of medicinal chemistry.

Clinical applications of 3′‐azido‐2′,3′‐ dideoxythymidine (AZT) and related dideoxynucleosides

S. Broder, 1990, Medicinal research reviews.

Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.

S. Broder, R. Yarchoan, D. Cooney, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

S. Broder, J. Balzarini, D. Cooney, 1986, Biochemical pharmacology.

The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.

D. Vistica, S. Broder, F. Balis, 1987, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus.

S. Broder, 1990, The American journal of medicine.

2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV).

H. Mitsuya, S. Broder, J. Roth, 1987, Biochemical pharmacology.

Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future.

H. Mitsuya, S. Broder, C. Perno, 1991, Blood.

NIH conference. Antiretroviral therapy in AIDS.

H. Mitsuya, S. Broder, G. Pavlakis, 1990, Annals of internal medicine.

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.

H. Mitsuya, S. Broder, C. Perno, 1989, Science.

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

H. Mitsuya, S. Broder, R. Yarchoan, 1989, The New England journal of medicine.

Alpha, beta- and beta, gamma-methylene 5'-phosphonate derivatives of 3'-azido-2',3'-dideoxythymidine-5'-triphosphate. Correlation between affinity for reverse transcriptase, susceptibility to hydrolysis by phosphodiesterases and anti-retrovirus activity.

E. De Clercq, R. Pauwels, P. Herdewijn, 1988, Biochemical pharmacology.

Chapter 26. Therapeutic Strategies in the Treatment of AIDS

H. Mitsuya, S. Broder, R. Yarchoan, 1988 .

Potential Anti-AIDS Drugs. 2′,3′-Dideoxycytidine Analogues.

H. Mitsuya, S. Broder, V. Marquez, 1987 .

Strategies for antiviral therapy in AIDS

H. Mitsuya, S. Broder, 1987, Nature.

Acid-Stable 2′-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV.

H. Mitsuya, S. Broder, J. Roth, 1990 .

A pilot study of 2′,3′‐dideoxyinosine for the treatment of chronic hepatitis B

J. Hoofnagle, H. Mitsuya, S. Broder, 1992, Hepatology.

Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine.

E. De Clercq, R. Pauwels, P. Herdewijn, 1986, Biochemical and biophysical research communications.

In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells.

S. Broder, D. Gilbert, D. Cooney, 1991, The Journal of infectious diseases.

2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine.

H. Mitsuya, S. Broder, C. Perno, 1990, Molecular pharmacology.

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.

B. Anderson, H. Mitsuya, S. Broder, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.

D. Venzon, H. Mitsuya, S. Broder, 1995, The Journal of infectious diseases.

Progress and challenges in the global effort against cancer

S. Broder, 1991, Journal of Cancer Research and Clinical Oncology.

Challenges in the therapy of HIV infection.

H. Mitsuya, S. Broder, R. Yarchoan, 1993, Trends in pharmacological sciences.

Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.

D. Venzon, S. Broder, J. Karp, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges in the therapy of HIV infection.

H. Mitsuya, S. Broder, R. Yarchoan, 1993, Immunology today.

Dideoxycytidine (ddC): a potent antiretroviral agent for human immunodeficiency virus infection. An introduction.

S. Broder, 1990, The American journal of medicine.

Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.

M. Reitz, H. Mitsuya, S. Broder, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Principles of Antiretroviral Therapy for AIDS and Related Diseases

S. Broder, J. Balzarini, 1988 .

2',3'-Dideoxyadenosine is selectively toxic for TdT-positive cells.

H. Mitsuya, S. Broder, N. Landau, 1988, Blood.

Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide.

S. Broder, S. H. Wilson, C. Stein, 1989, Biochemistry.

Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV).

H. Mitsuya, G. Zon, S. Broder, 1988, Gene.

1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus.

H. Mitsuya, S. Broder, A. Dalgleish, 1989, Journal of medicinal chemistry.

EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO

E. Gelmann, R. Redfield, L. Resnick, 1985, The Lancet.

Abasic oligodeoxyribonucleoside phosphorothioates: synthesis and evaluation as anti-HIV-1 agents.

G. Zon, S. Broder, R. Iyer, 1990, Nucleic acids research.

Progress in the Molecular Medicine of Cancer

S. Broder, 1995 .

New directions in molecular medicine.

S. Broder, J. Karp, 1994, Cancer research.

Targeted therapy of human immunodeficiency virus‐related disease

H. Mitsuya, S. Broder, R. Yarchoan, 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Antiretroviral Therapy in AIDS

H. Mitsuya, S. Broder, G. Pavlakis, 1990 .

Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides.

H. Mitsuya, S. Broder, S. Aaronson, 1987, Proceedings of the National Academy of Sciences of the United States of America.

RESPONSE OF HUMAN-IMMUNODEFICIENCY-VIRUS-ASSOCIATED NEUROLOGICAL DISEASE TO 3'-AZIDO-3'-DEOXYTHYMIDINE

S. Larson, J. Grafman, A. Brunetti, 1987, The Lancet.

A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.

D. Venzon, S. Broder, O. Brawley, 1993, The Journal of infectious diseases.

Immunologic issues in anti-retroviral therapy.

H. Mitsuya, S. Broder, R. Yarchoan, 1990, Immunology today.

Progress against cancer

S. Broder, J. Karp, 2005, Journal of Cancer Research and Clinical Oncology.

Microbial disease in humans: A genomic perspective.

R. Mural, J. Venter, G. Subramanian, 2001 .

Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium.

J. Venter, S. Broder, J C Venter, 2000, Annual review of pharmacology and toxicology.

Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI).

H. Mitsuya, S. Broder, R. Yarchoan, 1990, AIDS research and human retroviruses.

Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction.

H. Mitsuya, S. Broder, R. Yarchoan, 1992, AIDS research and human retroviruses.

The occurrence of opportunistic non-Hodgkin's lymphomas in the setting of infection with the human immunodeficiency virus.

S. Broder, R. Yarchoan, J. Pluda, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Configuration and expression of the T cell receptor beta chain gene in human T-lymphotrophic virus I-infected cells

M. Reitz, H. Mitsuya, S. Broder, 1986, The Journal of experimental medicine.

Generation of Antigen-specific Helper-inducer Clones .

M. Reitz, H. Mitsuya, S. Broder, 2003 .

Infection of human T lymphotropic virus-I-specific immune T cell clones by human T lymphotropic virus-I.

M. Reitz, H. Mitsuya, S. Broder, 1986, The Journal of clinical investigation.

Defect in IgA secretion and in IgA specific suppressor cells in patients with selective IgA deficiency.

T. Waldmann, S. Broder, M. Durm, 1976, Transactions of the Association of American Physicians.

Suppressor T cells in the pathogenesis of hypogammaglobulinemia associated with a thymoma.

T. Waldmann, S. Broder, M. Durm, 1975, Transactions of the Association of American Physicians.

Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects.

H. Mitsuya, S. Broder, A. Fisher, 1986, Science.

Antiviral therapy against HIV infection.

H. Mitsuya, S. Broder, R. Yarchoan, 1990, Journal of the American Academy of Dermatology.

Clinical course of retrovirus-associated adult T-cell lymphoma in the United States.

W. Blattner, E. Jaffe, P. Bunn, 1983, The New England journal of medicine.

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

W. Wilson, S. Broder, I. Feuerstein, 1995, The Lancet.

Application of the Human Genome to Obstetrics and Gynecology

J. Venter, T. Woodage, S. Broder, 2002, Clinical obstetrics and gynecology.

Abnormalities of immunoregulatory cells in immunodeficiency disease and cancer.

T. Waldmann, S. Broder, L. Muul, 1981, Progress in clinical and biological research.

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

Trevor Hastie, Paul Cane, Hongyue Dai, 2008, BMC Cancer.

T cell disorders in primary immunodeficiency diseases

T. Waldmann, S. Broder, 1978, Springer Seminars in Immunopathology.

Regression of a T-cell lymphoma after administration of antithymocyte globulin.

R. Fisher, S. Broder, R. Young, 1978, Annals of internal medicine.

Microbial Disease in Humans: A Genomic Perspective

J. Craig Venter, R. Mural, J. Venter, 2012, Molecular Diagnosis.

Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I.

M. Reitz, H. Mitsuya, S. Broder, 1986, The Journal of clinical investigation.

Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection.

H. Mitsuya, S. Broder, R. Yarchoan, 1989, The American journal of medicine.

Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease

S. Larson, J. Grafman, M. Dalakas, 1988, Annals of neurology.

Immunologic enhancement of tumor xenografts by pepsin-degraded immunoglobulin.

S. Broder, F. Whitehouse, 1969, Science.

Cellular regulation of immune function.

S. Broder, 1980, The Journal of allergy and clinical immunology.

Suppressor cells in neoplastic disease.

T. Waldmann, S. Broder, L. Muul, 1978, Journal of the National Cancer Institute.

FOLLOW-UP OF NEUROPATHY FROM 2',3'-DIDEOXYCYTYTIDINE

M. Dalakas, S. Broder, R. Dubinsky, 1988, The Lancet.

The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma.

T. Waldmann, R. Macdermott, S. Broder, 1976, Federation proceedings.

Sequence analysis of the human genome: implications for the understanding of nervous system function and disease.

J. Venter, G. Subramanian, A. Cravchik, 2001, Archives of neurology.

Suppression of retroviral propagation and disease by suramin in murine systems.

S. Broder, W. Haseltine, R. Ruprecht, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I.

M. Reitz, S. Matsushita, H. Mitsuya, 1987, The Journal of clinical investigation.

Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C.

Olivia T. Abar, S. Friedman, J. Catanese, 2006, Gastroenterology.

Controlled trial methodology and progress in treatment of the acquired immunodeficiency syndrome (AIDS). A quid pro quo.

S. Broder, 1989, Annals of internal medicine.

HIV: Antiviral Chemotherapy

S. Broder, 1989 .

Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I.

S. Matsushita, H. Mitsuya, S. Broder, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Genomics, science and medicine: the future is now

S. Broder, 2001 .

The Bethesda system for reporting cervical/vaginal cytologic diagnosis–report of the 1991 bethesda workshop

S. Broder, 1992, The Journal of family practice.

Progress in the development of antiviral therapy for HTLV-III-associated diseases.

S. Broder, R. Yarchoan, 1987, Important advances in oncology.

Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection.

Olivia T. Abar, S. Friedman, J. Catanese, 2009, Journal of hepatology.

Immunoregulatory functions of cultured human T lymphocytes.

T. Waldmann, S. Broder, G. Bonnard, 1980, Transactions of the Association of American Physicians.

Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression.

G. Shaw, S. Broder, M. Essex, 1984, Advances in internal medicine.

Cigarette advertising and corporate responsibility.

S. Broder, 1992, JAMA.

Perspectives on Cancer in Japan and the United States'

S. Broder, 1993, Japanese journal of cancer research : Gann.

Familial chronic lymphocytic leukemia. Immunologic and cellular characterization.

W. Blattner, S. Broder, A. Muchmore, 1976, Annals of internal medicine.

Disorders of Suppressor T Cells in Immunodeficiency and Malignancy

T. Waldmann, S. Broder, M. Durm, 1980 .

CHAPTER 5 – T-T INTERACTIONS IN THE GENERATION OF HUMAN SUPPRESSOR EFFECTOR CELLS IN VITRO

T. Waldmann, S. Broder, M. Durm, 1979 .

Reactivity of lupus erythematosus antibodies with leukemic helper T cells.

A. Ahmed, S. Broder, A. Steinberg, 1978, The Journal of investigative dermatology.

Cures for the Third World's problems

S. Hoffman, P. Hotez, S. Broder, 2002, EMBO reports.

The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnosis—Report of the 1991 Bethesda Workshop

S. Broder, 1992 .

Fraud in breast-cancer trials.

S. Broder, 1994, The New England journal of medicine.

Differences in the interaction of HIV-1 and HIV-2 with CD4.

R. Redfield, H. Mitsuya, S. Broder, 1990, Journal of acquired immune deficiency syndromes.

The human costs of cancer and the response of the national cancer program

S. Broder, 1991, Cancer.

Whole genomes: the foundation of new biology and medicine.

J. Venter, S. Broder, J C Venter, 2000, Current opinion in biotechnology.

Pathogenic human retroviruses.

S. Broder, 1988, The New England journal of medicine.

Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage

A. Foli, S. Broder, R. Yarchoan, 1994 .

Fc-IgM and Fc-IgG receptors on human circulating B lymphocytes.

S. Broder, W. Pichler, 1978, Journal of immunology.

Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma.

T. Waldmann, E. Jaffe, V. Devita, 1981, Gastroenterology.

NEUROLOGICAL INVOLVEMENT IN AIDS: TREATMENT

S. Larson, J. Grafman, M. Dalakas, 2004 .

Clinical applications of 3′‐azido‐2′,3′‐ dideoxythymidine (AZT) and related dideoxynucleosides

S. Broder, 1990, Medicinal research reviews.

Unusual clonal evolution in a case of chronic myelogenous leukemia.

J. Whang‐Peng, S. Broder, R. Young, 1976, Acta Haematologica.

Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection.

S. Broder, R. Yarchoan, T. Lawley, 1989, Journal of the American Academy of Dermatology.

Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'- dideoxynucleosides

S. Broder, C. Perno, R. Yarchoan, 1988, The Journal of experimental medicine.

Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody.

S. Broder, C. Perno, M. Currens, 1990, AIDS research and human retroviruses.

Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study.

G. di Chiro, M. Fulham, A. Brunetti, 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Genome-based biomarkers for adverse drug effects, patient enrichment and prediction of drug response, and their incorporation into clinical trial design.

A. Clark, S. Broder, T. White, 2006, Personalized medicine.

Antibodies to ganglioside GM1 induce mitogenic stimulation and cap formation in rat thymocytes

T. Waldmann, S. Broder, W. Pichler, 1978, European journal of immunology.

AIDS therapies.

S. Broder, R. Yarchoan, Hiroaki Mitsuya, 1988, Scientific American.

Interactions between radioresistant T Cells from plasmacytoma‐bearing mice and radiosensitive T Cells from normal mice leading to suppression

S. Broder, L. Muul, B. S. Roberson, 2007, Hematological oncology.

INTERACTIONS BETWEEN RADIORESISTANT T CELLS RADIOSENSITIVE T CELLS FROM NORMAL MICE LEADING TO SUPPRESSION FROM PLASMACYTOMA-BEARING MICE AND

S. Broder, Linda Mesler MUULt, Bob S. ROBERSONt, 2007 .

Fc-Receptors on Human T Lymphocytes

S. Broder, W. Pichler, Lawrence G. Lum, 1978, The Journal of Immunology.

FURTHER CHARACTERIZATION OF NEOPLASTIC HELPER T CELLS FROM PATIENTS WITH THE SÉZARY SYNDROME

T. Waldmann, S. Broder, C. Goldman, 1977 .

Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens

H. Mitsuya, S. Broder, R. Yarchoan, 1997, AIDS.